Good MorningEquities rebounded again on Wednesday gaining about 2.0% at the height of the session. The move was driven by better than expected data on the labor front as well as some less-hawkish than expected comments from Jerome Powell. On the labor front, the ADP employment report showed the addition of more than 1.0 million new jobs to the economy when adjusted for revisions. The data is more than double the expectations and points to even tighter labor market conditions than previously thought. The NFP is due out on Friday and could reveal the same information. The risk with the NFP is that wage gains are expected to top 6.0% on a YOY basis and drive consumer-level inflation this year.
Elsewhere in the markets, the price of West Texas Intermediate surged more than 3.0% on Wednesday to above $113 per barrel. This is the highest level for WTI in over a decade and prices are expected to keep rising. Based on the technical outlook, the price of WTI will move above $120 very soon and will be another driving force of inflation this year. Featured: Trump’s betrayal exposed (Ad) 
|
Politics | | | Global stock markets were mixed Thursday and oil prices jumped another $5 as Russian forces whose attack on Ukraine has roiled financial markets bombarded the country’s second-largest city and besieged two ports.
The economic fallout from the Russian invasion expanded, with Fitch Rati... Read the Full Story |
|
From Our Partners | | It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential.
We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks.
Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap.
And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it. | | The Most Profitable Phase of Crypto Just Started - PLUS Claim your $10 in Bitcoin |
|
Politics | | | Wall Street took another sharp swing Wednesday, this time back to rally mode, as stocks and Treasury yields rose even as U.S. crude oil prices climbed to the highest level in more than a decade.
The S&P 500 rose 1.9%, recouping its losses from earlier in the week, after Federal Re... Read the Full Story |
|
Markets | | | Even blue chip names such as those in the Dow Jones index have been unusually volatile in recent days. For the long-term investor, it means quality stocks like The Home Depot, NIKE, and 3M are now worth invading. Read the Full Story |
|
From Our Partners | | MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $200 off your 2025 subscription. Free for 30 days. | | Start Your Risk-Free Trial Here |
|
Markets | | | As we move into the month of March, dividend stocks remain some of the strongest options to consider in the current market environment. Whether you are concerned about the impacts of inflation or simply want to own stocks that are known to hold up well during volatility, adding dividend-payers to your strategy Read the Full Story |
|
Politics | | | The latest developments on the Russia-Ukraine war:
BRUSSELS — A senior European Union official says that in the wake of Ukraine’s formal application this week to join the bloc, bids for entry are also expected “imminently” from Moldova and Georgia.
The two eastern Europ... Read the Full Story |
|
From Our Partners | | Top institutions are raising their year-end targets for one of the biggest assets out there…
Several weeks ago, Standard Chartered’s Head of Digital Assets revised his target for Q2 2025 from $120k… openly acknowledging $200K is in play.
And with the kind of momentum we’ve seen from this top asset - Bitcoin - in recent weeks, I wouldn’t be surprised if it hits that target in the coming months.
In fact, from what I’m seeing, the stars are aligned for a bull run… and its next leg up could be just around the corner. | | Just tap this link and you’ll be all set. |
|
Stocks | | | The analysts still love Salesforce.com (NYSE: CRM) despite the round of price target reductions it just received. The company reported a stellar quarter and raised its guidance but the analyst still felt the need to adjust their targets. Read the Full Story |
|
Politics | | | The number of people who have fled Ukraine since Russian forces invaded on Feb. 24 has reached 1 million, the U.N. refugee agency said Wednesday.
The tide of people fleeing Ukraine — by car, train and on foot — marks the swiftest exodus of refugees this century. Shabia Mantoo, spokes... Read the Full Story |
|
Markets | | | Ordinary Russians are feeling the painful effects of the West imposing sanctions on Russia over its invasion of Ukraine, including payment systems that won’t operate, problems in being able to withdraw cash and difficulty in purchasing certain items Read the Full Story |
|
Stocks | | | Shares of Ross Stores (NASDAQ: ROST) are moving up because of a combination of factors that include performance, capital returns, and a greatly improved outlook for long-term growth. The company says that, due to changes within the industry, they are now forecasting as much as 20% more growth over the long term than they were previously. Read the Full Story |
|
Markets | | | Visual social media lifestyle brand platform Pinterest (NYSE: PINS) stock has fallen over (-60%) off its pandemic highs of $90.09. To the disappointment of investors, the Company experienced a (-6%) drop in monthly active users (MAUs) despite having 431 million worldwide users in Q4 2021. While Pint... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. | | View Today's Stock Pick |
|
